FRAŇKOVÁ, Soňa, Petr URBÁNEK, Petr HUSA, Vratislav NĚMEČEK, Homie RAZAVI, Devin RAZAVI-SHEARER, Roman CHLÍBEK and Jan ŠPERL. Chronic hepatitis C in the Czech Republic: forecasting the disease burden. Central European Journal of Public Health. Prague: Tigis s.r.o., 2019, vol. 27, No 2, p. 93-98. ISSN 1210-7778. Available from: https://dx.doi.org/10.21101/cejph.a5350.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Chronic hepatitis C in the Czech Republic: forecasting the disease burden
Authors FRAŇKOVÁ, Soňa (203 Czech Republic, guarantor), Petr URBÁNEK (203 Czech Republic), Petr HUSA (203 Czech Republic, belonging to the institution), Vratislav NĚMEČEK (203 Czech Republic), Homie RAZAVI (840 United States of America), Devin RAZAVI-SHEARER (840 United States of America), Roman CHLÍBEK (203 Czech Republic) and Jan ŠPERL (203 Czech Republic).
Edition Central European Journal of Public Health, Prague, Tigis s.r.o. 2019, 1210-7778.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30303 Infectious Diseases
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 0.653
RIV identification code RIV/00216224:14110/19:00110345
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.21101/cejph.a5350
UT WoS 000472898100002
Keywords in English hepatitis C;disease burden;epidemiology;Czech Republic
Tags 14110214, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 31/1/2020 10:36.
Abstract
Objective: Chronic HCV infection is associated with cirrhosis of the liver, hepatocellular carcinoma (HCC), and liver transplantation. HCV disease burden and the impact of new potent direct acting antivirals (DAAs) in the Czech Republic are unknown. Methods: Using a modelling framework, HCV disease progression in the Czech Republic was predicted to 2030 under the current standard of care treatment structure. In addition, two strategies to reduce the future burden of HCV infection were modelled: an incremental increase in treatment annually and WHO targets. Results: The number of viremic infected individuals in the Czech Republic is estimated to peak in 2026 (n = 55,130) and to decline by 0.5% by 2030 (n = 54,840). The number of individuals with compensated cirrhosis (n = 1,400), decompensated cirrhosis (n = 80), HCC (n = 70), and liver related deaths (n = 60) is estimated to more than double by 2030. Through aggressive increases in diagnosis and treatment, HCV related mortality may decrease by 70% by 2030. Conclusions: Disease burden associated with chronic HCV infection is projected to peak in the Czech Republic in 30-40 years. Assuming that the current portion of DAAs used remains constant, a significant reduction in HCV disease burden is possible through increased diagnosis and treatment through 2030. This analysis provides evidence in order to facilitate the development of national strategies for HCV care and management in the Czech Republic.
PrintDisplayed: 21/7/2024 11:30